Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)

被引:99
作者
Litvinenko I.V. [1 ]
Odinak M.M. [1 ]
Mogil'naya V.I. [1 ]
Emelin A.Y.U. [1 ]
机构
[1] Department of Nervous Diseases, Military Medical Academy, St. Petersburg
关键词
Dementia; Galantamine; Parkinson's disease;
D O I
10.1007/s11055-008-9077-3
中图分类号
学科分类号
摘要
An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (p < 0.05),ADAS-cog (p < 0.05), the clock drawing test (p < 0.05), and the FAB (p < 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (p = 0.0002), anxiety (p = 0.04), sleep disturbance (p = 0.04), and apathy (p = 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (p = 0.007) and improvements in daily activity (p = 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%). © Springer Science+Business Media, Inc. 2008.
引用
收藏
页码:937 / 945
页数:8
相关论文
共 42 条
[1]  
Glozman Zh.M., Levin O.S., Mental disorders in extrapyramidal diseases, Extrapyramidal Diseases: Handbook of Diagnosis and Treatment, pp. 74-86, (2002)
[2]  
Golubev V.L., Levin Ya.I., Vein A.M., Parkinson's Disease and Parkinson's Syndrome, (1999)
[3]  
Levin O.S., Amosova N.A., Psychotic Disorders in Parkinson's Disease. Scientific-Practical Conference on Parkinson's Disease, pp. 30-32, (1999)
[4]  
Levin O.S., Efficacy of Reminyl in dementia with Lewy bodies, Zh. Nevropatol. Psikhiat., 105, 10, pp. 15-21, (2005)
[5]  
Aarsland D., Larsen J.P., Cumming J.L., Et al., Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease, Arch. Neurol., 56, 3, pp. 595-601, (1999)
[6]  
Aarsland D., Andersen K., Larsen J.P., Et al., Risk of dementia in Parkinson's Disease: A community-based prospective study, Neurology, 56, 6, pp. 730-736, (2001)
[7]  
Aarsland D., Hutchinson M., Larsen J.P., Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia, Int. J. Geriat. Psychiat., 18, 10, pp. 937-941, (2003)
[8]  
Ballard C., Piggott M., Johnson M., Delusions associated with elevated muscarinic binding in dementia with Lewy bodies, Ann. Neurol., 48, 6, pp. 868-876, (2000)
[9]  
Beach S.R., Schulz R., Caregiving as a risk factor for mortality: The Caregiver Health Effects Study, J. Amer. Med. Assoc., 282, 23, pp. 2215-2219, (1999)
[10]  
Bohnen N.I., Kaufer D.I., Ivanco L.S., Et al., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study, Arch Neurol., 60, 12, pp. 1745-1748, (2003)